Provided by Tiger Trade Technology Pte. Ltd.

LivaNova PLC

67.89
+0.47000.70%
Volume:891.63K
Turnover:60.39M
Market Cap:3.71B
PE:-17.01
High:68.25
Open:67.47
Low:66.79
Close:67.42
52wk High:68.25
52wk Low:32.48
Shares:54.61M
Float Shares:54.41M
Volume Ratio:1.11
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9912
EPS(LYR):1.16
ROE:-17.63%
ROA:5.24%
PB:3.20
PE(LYR):58.53

Loading ...

Earning Preview: LivaNova PLC this quarter’s revenue is expected to increase by 9.03%, and institutional views are Hold

Earnings Agent
·
Feb 18

Piper Sandler Sticks to Their Buy Rating for LivaNova (LIVN)

TIPRANKS
·
Yesterday

A Look At LivaNova (LIVN) Valuation After KeyBanc Upgrade And Renewed Medtech Optimism

Simply Wall St.
·
Feb 03

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and LivaNova (LIVN)

TIPRANKS
·
Jan 26

LivaNova plc to Announce Fourth-Quarter and Full-Year Results

Reuters
·
Jan 20

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

THOMSON REUTERS
·
Jan 20

LivaNova Chief Legal Officer Michael Hutchinson Resigns

Reuters
·
Jan 14

LivaNova (LIVN) Is Up 6.2% After Fresh Analyst Optimism on Advanced Therapies Portfolio - What's Changed

Simply Wall St.
·
Jan 11

LivaNova Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Jan 09

LivaNova price target raised to $66 from $56 at Goldman Sachs

TIPRANKS
·
Jan 09

Barclays Reaffirms Their Hold Rating on LivaNova (LIVN)

TIPRANKS
·
Jan 09

LivaNova (LIVN): Reassessing Valuation After KeyBanc’s Overweight Initiation and Growth Outlook

Simply Wall St.
·
Dec 22, 2025

KeyBanc Initiates LivaNova at Overweight With $81 Price Target

MT Newswires Live
·
Dec 19, 2025

LivaNova Initiated at Overweight by Keybanc

Dow Jones
·
Dec 19, 2025

LivaNova Plc : Keybanc Initiates Coverage With Overweight Rating and Target Price $81

THOMSON REUTERS
·
Dec 19, 2025

Assessing LivaNova (LIVN)’s Valuation After Hiring ResMed Veteran to Lead Sleep Apnea Commercialization

Simply Wall St.
·
Dec 15, 2025

The Bull Case For LivaNova (LIVN) Could Change Following Medicare VNS Boost And New OSA Leader

Simply Wall St.
·
Dec 09, 2025

LivaNova Highlights CORE-VNS Study Showing VNS Therapy Reduces Seizure Frequency and Healthcare Costs in Drug-Resistant Epilepsy

Reuters
·
Dec 03, 2025

LivaNova Names Lucile Blaise Global Head of Commercialization for Obstructive Sleep Apnea

Reuters
·
Dec 02, 2025

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

THOMSON REUTERS
·
Dec 02, 2025